FUND+ PEOPLE INVESTMENT STRATEGY PORTFOLIO YOUR PROJECT NEWS CONTACT US Our Mission Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium. We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact. News Recent Posts ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors December 2, 2021 Confo Therapeutics Enters Collaborative Agreement with Regeneron November 30, 2021 Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis November 22, 2021 Contact us Address: Groot Begijnhof 60 3000 Leuven Belgium Phone: +32 (0)16 90 50 00 Email: info@fundplus.be Recent Articles ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Confo Therapeutics Enters Collaborative Agreement with Regeneron Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis © 2019 FUND+- ALL RIGHTS RESERVED. | We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPTRead More

FUND+ PEOPLE INVESTMENT STRATEGY PORTFOLIO YOUR PROJECT NEWS CONTACT US EXITS What services do we provide? EXITS The below list includes all exits companies managed by Fund+ Ogeda S.A. was acquired by Astellas in April 2017. WEBSITE Contact us Address: Groot Begijnhof 60 3000 Leuven Belgium Phone: +32 (0)16 90 50 00 Email: info@fundplus.be Recent Articles ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Confo Therapeutics Enters Collaborative Agreement with Regeneron Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis © 2019 FUND+- ALL RIGHTS RESERVED. | We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPTRead More

FUND+ PEOPLE INVESTMENT STRATEGY PORTFOLIO YOUR PROJECT NEWS CONTACT US CONTACT US GET IN TOUCH Feel free to contact us with your questions or if you would like to setup a meeting. Company Name (required) Your Name (required) Your Email (required) Phone (required) Your Message (required) Message... ADDRESS & MAP Groot Begijnhof 60, 3000 Leuven (Belgium) Tel: +32 (0)16/90.50.00 | info@fundplus.be Offices accessible via the Zwartzusterstraat Contact us Address: Groot Begijnhof 60 3000 Leuven Belgium Phone: +32 (0)16 90 50 00 Email: info@fundplus.be Recent Articles ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Confo Therapeutics Enters Collaborative Agreement with Regeneron Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis © 2019 FUND+- ALL RIGHTS RESERVED. | We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPTRead More